COVID-19 pandemic
Mexican health regulator COFEPRIS grants emergency use authorization for Merck & Co.'s anti-COVID-19 drug Molnupiravir for the treatment of severe disease.
/cloudfront-us-east-2.images.arcpublishing.com/reuters/OWONSDP4GRPLZHGRIWIWIAYD3Y.jpg "Mexico grants emergency use approval for Merck's COVID-19 pill © Reuters")
Sources: Reuters
Changes
- Mexican health regulator COFEPRIS grants the emergency use authorization of Merck & Co.'s anti-COVID-19 drug Molnupiravir to treat severe disease.
- Mexican health regulator COFEPRIS grants emergency use authorization for Merck & Co.'s anti-COVID-19 drug Molnupiravir for the treatment of severe disease.